Retatrutide vs Liraglutide: Research Comparison (UK 2026)

At a glance

Property	Retatrutide	Liraglutide
Receptor profile	Triple GIP / GLP-1 / glucagon	GLP-1 monoagonist
Developer	Eli Lilly	Novo Nordisk
UK regulatory status	Not approved — research only	MHRA-licensed (Saxenda 3 mg — obesity; Victoza — T2D)
Mean weight reduction	≈24% at 48 weeks (Phase 2, 12 mg)	≈8% at 56 weeks (SCALE Obesity, 3 mg)
Dosing frequency	Once weekly SC injection	Once daily SC injection
Half-life	≈6 days	≈13 hours
Glycaemic control	Robust reduction in Phase 2	Moderate reduction; Victoza licensed for T2D
Cardiovascular outcome data	None published	LEADER: 13% MACE reduction (T2D, 1.8 mg arm)
Notable side-effect signal	GI + modest heart-rate increase (Phase 2)	GI (especially initiation nausea); injection-site reactions

Receptor pharmacology

Liraglutide was developed in the mid-2000s as an acylated GLP-1 analogue — a structural modification of the endogenous 7-37 peptide at position 26 (lysine replaced; C16 fatty acid attached) and position 34 (arginine replaced by lysine) to resist DPP-4 cleavage and extend half-life through albumin binding. Its pharmacological action is entirely mediated through GLP-1 receptor agonism: enhanced glucose-dependent insulin secretion, suppressed postprandial glucagon, decelerated gastric emptying, and hypothalamic appetite suppression. This single-receptor mechanism, combined with a 13-hour half-life necessitating daily injection, represents the template from which subsequent incretin agents departed.

Retatrutide occupies a qualitatively different position in incretin pharmacology, engaging three distinct receptor systems within one molecule. GIP receptor agonism adds a second incretin pathway and direct adipocyte effects; glucagon receptor agonism introduces a hepatic energy-expenditure signal that no GLP-1 monoagonist, including liraglutide, can provide. The net effect — demonstrated in Phase 2 but not yet confirmed across larger Phase 3 populations — is that energy intake and energy expenditure are simultaneously modulated, producing weight reductions approximately three times larger than those seen with liraglutide in controlled trials.

For pharmacology researchers, this comparison is particularly instructive because it spans three generations of incretin drug design: liraglutide (single receptor, daily dosing, 2009 approval), semaglutide (single receptor, optimised albumin binding, weekly dosing, 2017), tirzepatide (dual receptor, weekly, 2022), and now retatrutide (triple receptor, weekly, Phase 3). Each iteration has produced roughly additive improvements in weight outcomes, suggesting continued mechanistic yield from receptor diversification.

Clinical evidence base

Liraglutide 3 mg was evaluated in the SCALE programme across four large trials. SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015; n = 3,731) reported 8.4% mean weight loss from baseline at 56 weeks, compared with 2.8% on placebo — a placebo-subtracted reduction of approximately 5.4 percentage points. Approximately 63% of participants on liraglutide achieved ≥5% weight loss. SCALE Diabetes (2015) assessed efficacy in T2D. The SCALE SLEEP study added evidence in sleep apnoea. The LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016; n = 9,340 with T2D) demonstrated a 13% MACE reduction, though at the 1.8 mg diabetic dose rather than the 3 mg obesity dose.

Retatrutide's primary dataset (Jastreboff et al., NEJM 2023; n = 338; 48 weeks) was a Phase 2 dose-ranging study. The 12 mg arm produced a mean weight reduction of 24.2%, with the study population predominantly without diabetes. Phase 3 TRIUMPH trials are ongoing as of 2026, with no head-to-head comparison against liraglutide registered. The evidence gap is therefore not merely quantitative — it reflects approximately fifteen years of post-marketing experience and multiple independent trial programmes for liraglutide versus a single Phase 2 study for retatrutide.

Safety signals

Liraglutide's safety profile is among the most thoroughly characterised of any obesity pharmacotherapy. Gastrointestinal adverse events — predominantly nausea at initiation, followed by diarrhoea and constipation — are the primary tolerability concern and the most common reason for discontinuation. The class warning for thyroid C-cell tumours (based on rodent carcinogenicity data) applies. Post-marketing pharmacovigilance spanning over a decade has identified rare cases of acute pancreatitis, though causality remains contested. Injection-site reactions occur more frequently with daily administration than with weekly agents.

Retatrutide Phase 2 data showed a qualitatively similar GI profile. The distinctive safety finding was a dose-dependent resting heart-rate increase of 3–6 bpm in the 8 mg and 12 mg arms, attributable to glucagon receptor agonism. This signal was absent from liraglutide across all SCALE trials and remains an open regulatory question pending Phase 3 safety data.

Which to prioritise for research

The primary utility of this comparison is in mapping the speed and direction of incretin pharmacology evolution rather than in informing clinical decision-making. Liraglutide is the appropriate compound when researchers need a well-characterised, MHRA-approved GLP-1 comparator with long-term safety data, cardiovascular outcomes evidence, and a decade of post-marketing pharmacovigilance. Retatrutide is the appropriate compound when the research question concerns the upper bound of receptor diversification and whether GIP plus glucagon co-agonism yields clinically superior outcomes relative to GLP-1 alone — with the caveat that Phase 3 evidence is not yet available. Placing these two compounds side by side makes the pace of incretin drug development over fifteen years immediately legible.